Search

News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations

In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new −⁠ even revolutionary −⁠ drugs into clinical practice.

Source: Quality Life Even with Hemophilia 30. 9. 2020

News Aclidinium bromide improves the quality of life for COPD patients

The ON-AIR study conducted in real practice demonstrated the benefits of aclidinium bromide for the quality of life of patients with chronic obstructive pulmonary disease (COPD). It also assessed the impact of treatment on the severity of nocturnal and morning symptoms and their impact on daily activities.

Source: Treatment of Asthma and COPD 15. 7. 2020

News Quality of Life of Hemophiliacs and Ways to Improve It

Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.

Source: Hemophilia with Movement 21. 5. 2021

News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles

The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.

Source: Multiple Sclerosis 18. 11. 2020

News Rurioctocog Alfa Pegol vs. Non-factor Therapy –⁠ Report from Real Clinical Practice

The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.

Source: Hemophilia 8. 11. 2022

News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?

The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?

Source: Multiple Sclerosis 17. 12. 2020

News Position of Parenteral Therapy in Patients with Severe COVID-19 Disease

Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency requiring non-invasive or invasive pulmonary ventilation. Intensive care therapy is associated with a high risk of severe malnutrition. According to current recommendations by the European Society for Clinical Nutrition and Metabolism, parenteral therapy plays an important role in the nutrition of patients.

Source: Parenteral Nutrition 30. 3. 2021

News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients

The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.

Source: Parenteral Nutrition 16. 9. 2020

News Dupilumab in the Treatment of Severe Asthma in Real-World Practice

A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 20. 10. 2020

News Modern Techniques and MRI Markers in Multiple Sclerosis Imaging or How to Increase Specificity and Sensitivity of Examinations

MRI is a key component in the diagnosis of multiple sclerosis (MS). However, despite significant progress in imaging methods, specificity is still not optimal. The current trend is to refine and clearly define MRI criteria for diagnosing multiple sclerosis and distinguishing it from MS-mimicking white matter lesions.

Source: Multiple Sclerosis 26. 5. 2020

News Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction

Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.

Source: Chronic Heart Failure and Lipidology 7. 9. 2021

News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).

Source: Hematologic Malignancies 27. 4. 2022

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs –⁠ sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) –⁠ in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.

Source: Cardiovascular Continuum 18. 11. 2021

News Desirable Side Effects of Antidiabetics

The days when diabetology was a field solely focused on normalizing blood sugar levels are long gone. Today, the approach in diabetology increasingly prioritizes influencing the patient's overall life prognosis, particularly reducing cardiovascular risk. What can be the desirable side effects of the main groups of antidiabetics that are not related to merely lowering glucose levels?

Source: Diabetes 6. 11. 2020

News Diosmin –⁠ Still an Important Modality in the Treatment of Venous Insufficiency

Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately, it remains without causal treatment. In the recommended therapeutic procedures, especially in the initial stages, compression treatment supplemented with pharmacotherapy plays a key role. This includes the administration of medicinal products containing micronized diosmin. The following text summarizes basic findings about its properties that predispose it to clinical use.

Source: Venous Insufficiency 3. 1. 2020